Venus Remedies ties up with Teva

Venus Remedies has entered into a collaborative agreement with Teva, the largest manufacturer of generic drugs in the world, for anti-cancer drug in the Canadian market. The high-potential drug is under patent protection till 2016. Under this collaboration, Venus will be initially manufacturing the drug at the Venus Medicine Research Centre, its research unit, for assisting Teva in registrations. Thereafter, it will also use its manufacturing capabilities to support Teva in enhancing the business from this drug in the Canadian market.